These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17229335)

  • 1. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
    J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
    Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
    Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
    Duvic M; Geskin L; Prince HM
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
    Kadin ME; Vonderheid EC
    Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
    [No Abstract]   [Full Text] [Related]  

  • 13. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
    Assaf C
    Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical experience with denileukin diftitox (ONTAK).
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.
    Foss F; Duvic M; Olsen EA
    Am J Hematol; 2011 Jul; 86(7):627-30. PubMed ID: 21674574
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
    Gerena-Lewis M; Crawford J; Bonomi P; Maddox AM; Hainsworth J; McCune DE; Shukla R; Zeigler H; Hurtubise P; Chowdhury TR; Fletcher B; Dyehouse K; Ghalie R; Jazieh AR
    Am J Clin Oncol; 2009 Jun; 32(3):269-73. PubMed ID: 19433964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
    Wong BY; Gregory SA; Dang NH
    Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.